Masimo (MASI)
(Delayed Data from NSDQ)
$111.53 USD
-2.74 (-2.40%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $111.67 +0.14 (0.13%) 6:48 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.53 USD
-2.74 (-2.40%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $111.67 +0.14 (0.13%) 6:48 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum C VGM
Zacks News
Masimo (MASI) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.
Digital Health M&As Gain Precedence in the New Normal
by Debanjana Dey
The booming digital health space has been witnessing significant M&A activities amid the pandemic.
Masimo's (MASI) Telehealth Solution Helps in COVID-19 Crisis
by Zacks Equity Research
Masimo (MASI) is lending support to Renown Health through Masimo SafetyNet in order to manage the COVID-19 surge.
Masimo (MASI) Releases Favorable Findings on Pulse Oximetry
by Zacks Equity Research
Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.
Masimo (MASI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 42.86% and 1.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results
Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.
Varian (VAR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal fourth-quarter performance.
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
Masimo (MASI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aphria (APHA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Aphria's (APHA) fiscal first-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment.
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
Masimo Unveils New Wearable Wireless Continuous Thermometer
by Zacks Equity Research
Masimo's (MASI) wearable wireless continuous thermometer offers consumers hassle-free continuous body temperature measurements, thereby eliminating the need for manual measurements.
Masimo's (MASI) Rad-G Pulse Oximeter Receives FDA Clearance
by Zacks Equity Research
Masimo's (MASI) Rad-G Pulse Oximeter receives FDA clearance, thereby allowing clinicians to access the most accurate and reliable pulse oximetry monitoring technologies.
Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval
by Zacks Equity Research
Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care
Masimo (MASI) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo Releases Favorable Study Results on Pulse Oximetry
by Zacks Equity Research
The pulse oximetry study result should be a major breakthrough for Masimo (MASI) to capture the neonatal patient care market.
Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness
by Zacks Equity Research
The FDA approval of Masimo's (MASI) PVi system will enable patient safety.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q2.